Lidocaine (GMP)

Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

Product Specifications

CAS Number

[137-58-6]

Product Name Alternative

Lignocaine (GMP)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; ERK; MEK; NF-κB; Sodium Channel

Type

GMP Small Molecules

Related Pathways

Apoptosis; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lidocaine-gmp.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=C(C)C=CC=C1C)CN(CC)CC

Molecular Formula

C14H22N2O

Molecular Weight

234.34

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582 (Pt 1) :11.|[2]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19 (1) :233.|[3]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113 (1) :31-6.|[4]Kadota S, et al. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. Eur Heart J. 2013 Apr;34 (15) :1147-56.|[5]Potet F, et al. GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Mol Pharmacol. 2020 Nov;98 (5) :540-547. |[6]Wang F, et al. In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment. Cells. 2022 Aug 11;11 (16) :2495.